Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price target boosted by Needham & Company LLC from $5.00 to $7.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating and issued a $7.00 price target on […]
Cantor Fitzgerald restated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a report released on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has a $7.00 target price on the stock. Separately, Needham & Company LLC lifted their target price on shares of Taysha Gene Therapies from $5.00 to $7.00 […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation. Insider & Institutional Ownership 25.9% of […]
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.